Advertisement

Pathology & Oncology Research

, Volume 23, Issue 2, pp 307–315 | Cite as

Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance

  • Jinfeng He
  • Wei Tan
  • Xuelian Tang
  • Jingping MaEmail author
Original Article

Abstract

Monitoring of non small cell lung cancer (NSCLC) patients on afatinib after acquired resistance to 1st generation tyrosine kinase inhibitors is important. Circulating tumor DNA (ctDNA) offers an attractive means other than conventional tissue biopsy to characterize real time dynamic changes of the disease. In our study, we aim to ascertain the clinical value for ctDNA monitoring of NSCLC patients with acquired resistance for afatinib treatment. 200 patients positive for the activating epithermal growth factor receptor (EGFR) mutations were recruited for the study. Baseline molecular profiling for L858R, Exon 19 deletion and T790M were performed. Thereafter, serial blood samples were taken and patients were assessed by overall survival (OS) to determine the usefulness of ctDNA monitoring. At baseline, matched tumor biopsy and ctDNA analysis had a concordance agreement of 93.5% for L858R and exon 19 deletion. We also determined that a large proportion of patients had the drug resistance mutation T790M prior to starting afatinib and these patients were linked to a worse survival outcome. For patients that registered a drop in ctDNA levels after afatinib was administered, we observed that their survival outcome was more favorable (hazard ratio 1.56, (95% CI 1.04 to 2.43). ctDNA levels were mostly elevated after the 3rd sampling cycle. Our results suggest that ctDNA can be used to predict the clinical benefits of afatinib treatment. Pre and post blood sampling aids to identify patient groups that may benefit most from the treatment and ctDNA is relatively sensitive to address the dynamic changes of the disease at the molecular level.

Keywords

Non small cell lung cancer (NSCLC) EGFR mutations Acquired resistance Afatinib ctDNA 

Notes

Acknowledgement

This work was supported by a research grant provided by the Jingzhou Central Hospital.

Compliance with Ethical Standards

Conflict of Interest

All other authors declare no conflict of interest.

Author’s Contribution

J.H and J.M designed the experiments. J.H, W.T and X.T performed the experiments and ctDNA analysis. J.H and J.M interpreted the data and wrote the manuscript.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

12253_2016_97_MOESM1_ESM.doc (797 kb)
Supplementary Figure 1. (DOC 797 kb)
12253_2016_97_MOESM2_ESM.doc (166 kb)
Supplementary Figure 2. (DOC 166 kb)
12253_2016_97_MOESM3_ESM.doc (468 kb)
Supplementary Figure 3. (DOC 468 kb)

References

  1. 1.
    Gazdar AF (2009) Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28(Suppl 1):S24–S31. doi: 10.1038/onc.2009.198 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Shigematsu H, Gazdar AF (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118(2):257–262. doi: 10.1002/ijc.21496 CrossRefPubMedGoogle Scholar
  3. 3.
    Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G, Yang PC (2014) A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 9 (2):154-162. doi: 10.1097/JTO.0000000000000033
  4. 4.
    Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290(16):2149–2158. doi: 10.1001/jama.290.16.2149 CrossRefPubMedGoogle Scholar
  5. 5.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L, National Cancer Institute of Canada Clinical Trials G (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123–132. doi: 10.1056/NEJMoa050753 CrossRefGoogle Scholar
  6. 6.
    Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, Henthorn L, Richards L (2001) Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 11(14):1911–1914CrossRefPubMedGoogle Scholar
  7. 7.
    Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62(20):5749–5754PubMedGoogle Scholar
  8. 8.
    Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol Off J Am Soc Clin Oncol 21(12):2237–2246. doi: 10.1200/JCO.2003.10.038 CrossRefGoogle Scholar
  9. 9.
    Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P (2004) Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 22 (16):3238-3247. doi: 10.1200/JCO.2004.11.057
  10. 10.
    Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H, Mitsudomi T (2006) Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib. Clin Cancer Res 12(19):5764–5769CrossRefPubMedGoogle Scholar
  11. 11.
    Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W (2006) Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors. Clin Cancer Res 12(21):6494–6501CrossRefPubMedGoogle Scholar
  12. 12.
    Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong, K K (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27 (34):4702-4711. doi:http://www.nature.com/onc/journal/v27/n34/suppinfo/onc2008109s1.html
  13. 13.
    Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR (2012) Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker. J Pharmacol Exp Ther 343(2):342–350CrossRefPubMedGoogle Scholar
  14. 14.
    Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102(21):7665–7670CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N (2013) LUX-Lung 4: a phase ii trial of afatinib in patients with advanced non–small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 31(27):3335–3341CrossRefPubMedGoogle Scholar
  16. 16.
    Taniguchi K, Uchida J, Nishino K, Kumagai T, Okuyama T, Okami J, Higashiyama M, Kodama K, Imamura F, Kato K (2011) Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas. Clin Cancer Res 17(24):7808–7815. doi: 10.1158/1078-0432.ccr-11-1712 CrossRefPubMedGoogle Scholar
  17. 17.
    Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz Jr LA (2008) Circulating mutant DNA to assess tumor dynamics. Nature Medicine 14 (9):985-990. http://www.nature.com/nm/journal/v14/n9/suppinfo/nm.1789_S1.html CrossRefPubMedGoogle Scholar
  18. 18.
    Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Janne PA, Lynch T, Johnson BE, Miller VA (2010) Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 28(2):357–360. doi: 10.1200/JCO.2009.24.7049 CrossRefGoogle Scholar
  19. 19.
    Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM, Jänne PA (2014) Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA. Clin Cancer Res 20(6):1698–1705CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Watanabe M, Kawaguchi T, S-I I, Ando M, Tamiya A, Kubo A, Saka H, Takeo S, Adachi H, Tagawa T, Kakegawa S, Yamashita M, Kataoka K, Ichinose Y, Takeuchi Y, Sakamoto K, Matsumura A, Koh Y (2015) Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR. Clin Cancer Res 21(15):3552–3560CrossRefPubMedGoogle Scholar
  21. 21.
    Kidess E, Heirich K, Wiggin M, Vysotskaia V, Visser BC, Marziali A, Wiedenmann B, Norton JA, Lee M, Jeffrey SS (2015) Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget 6(4):2549CrossRefPubMedGoogle Scholar
  22. 22.
    Szpechcinski A, Chorostowska-Wynimko J, Struniawski R, Kupis W, Rudzinski P, Langfort R, Puscinska E, Bielen P, Sliwinski P, Orlowski T (2015) Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease. Br J Cancer 113(3):476–483. doi: 10.1038/bjc.2015.225 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY, Ni J, Zhang HP, Zhang L, Luo J, Zhang J, Tang L, Su B, Chen G, Zhu G, Gu Y, Xu JF (2016) Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Report 6:20913. doi: 10.1038/srep20913 CrossRefGoogle Scholar
  24. 24.
    Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J (2009) Epidermal growth factor receptor mutations in plasma dna samples predict tumor response in chinese patients with stages iiib to iv non–small-cell lung cancer. J Clin Oncol 27(16):2653–2659CrossRefPubMedGoogle Scholar
  25. 25.
    Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, Koizumi F, Nishio K, Miyamoto K, Fujimura M, Nakao S (2007) Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 97(6):778–784. doi: 10.1038/sj.bjc.6603949 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, Brown H, Hammett T, Cantarini M, Barrett JC (2015) EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 90(3):509–515. doi: 10.1016/j.lungcan.2015.10.004 CrossRefPubMedGoogle Scholar
  27. 27.
    Yong E (2014) Cancer biomarkers: Written in blood. Nature 511(7511):524–526. doi: 10.1038/511524a CrossRefPubMedGoogle Scholar
  28. 28.
    De Grève J, Moran T, Graas M-P, Galdermans D, Vuylsteke P, Canon J-L, Schallier D, Decoster L, Teugels E, Massey D, Chand VK, Vansteenkiste J (2015) Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Lung Cancer 88(1):63–69. doi: 10.1016/j.lungcan.2015.01.013 CrossRefPubMedGoogle Scholar
  29. 29.
    Bar J, Botser D, Navon R, Peled N, Biran H, Gal-Yam EN, Ben-Arieh S, Raskin S, Onn A A Single-arm phase II study of afatinib treatment for advanced EGFR-mutant non-small cell lung cancer (mNSCLC) patients (pts) with EGFR-tyrosine kinase inhibitor (TKI) resistance. In: ASCO Annual Meeting Proceedings, 2015. vol 15_suppl. p e19031Google Scholar
  30. 30.
    Lee JY, Sun JM, Lim SH, Kim HS, Yoo KH, Jung KS, Song HN, Ku BM, Koh J, Bae YH, Lee SH, Ahn JS, Park K, Ahn MJ (2016) A phase Ib/II study of afatinib in combination with nimotuzumab in non-small cell lung cancer patients with acquired resistance to gefitinib or erlotinib. Clin Cancer Res 22(9):2139–2145. doi: 10.1158/1078-0432.CCR-15-1653
  31. 31.
    Zhang S, Zheng X, Huang H, Wu K, Wang B, Chen X, Ma S (2015) Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation. Oncotarget 6(8):5832CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DA (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359(4):366–377. doi: 10.1056/NEJMoa0800668 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, Stewart DJ, Hicks ME, Erasmus J Jr, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK (2011) The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 1(1):44–53. doi: 10.1158/2159-8274.CD-10-0010 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Jekunen AP (2015) Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments. J Oncol 2015:11. doi: 10.1155/2015/809835 CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2016

Authors and Affiliations

  • Jinfeng He
    • 1
  • Wei Tan
    • 2
  • Xuelian Tang
    • 1
  • Jingping Ma
    • 1
    Email author
  1. 1.Department of Respiratory Medicine, Jingzhou Central Hospital, The Second Clinical Medical CollegeYangtze UniversityJingzhouPeople’s Republic of China
  2. 2.Haemodialysis Centre, Jingzhou Central Hospital, The Second Clinical Medical CollegeYangtze UniversityJingzhouPeople’s Republic of China

Personalised recommendations